Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome

Journal of Clinical Psychopharmacology

Volumn 20, Issue 3, 2000, Pages 317-324

  Flockhart, David A ^a   Drici, Milou Daniel ^a   Kerbusch, Thomas ^a   Soukhova, Nadia ^a   Richard, Emily ^a   Pearle, Philip L ^b   Mahal, Subena K ^a   Babb, Victoria J ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PIMOZIDE;

ADULT; ARTICLE; BRONCHOPNEUMONIA; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG METABOLISM; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; PRIORITY JOURNAL; QT INTERVAL; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOTRANSFORMATION; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; CYTOCHROME P-450 CYP2D6; DEATH, SUDDEN, CARDIAC; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; GENOTYPE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PIMOZIDE; RABBITS; TOURETTE SYNDROME;

EID: 0034072788     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200006000-00005     Document Type: Article

References (50)

1. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
2. Lefebvre RA, Van Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokineties and electrocardiographic effect of astemizole. Br J Clin Pharmacol 1997;43:319-22.
3. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-1.
4. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788-90.
5. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
6. Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 1991;52:221-33.
7. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie MA. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-5.
8. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, Pessayre D. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983;32:1063-8.
9. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
10. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89: 235-8.
11. McCreadie RG, Heyants JJP, Chalmers A, Anderson AM. Plasma pimozide profiles in chronic schizophrenics. Br J Clin Pharmacol 1979;7:533-4.
12. Sou-yie C, Wilson DS, Guay DRP, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992;32:1045-9.
13. Flockhart DA, Buchert ET, Harris JW, Clauw DJ, Woosley RL. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1993;56:398-405.
14. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine, hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-58.
15. Harris JW, Rahman A, Kim B-Y, Guengerich FP, Collins JM. Metabolism by Taxol and human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
16. Ko J-W, Sukhova N, Thacker DL, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-62.
17. Bradford M. Determination of protein in small biological samples. Anal Biochem 1972;72:248-52.
18. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko J-W, Flockhart DA. Identification and characteristics of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285:428-37.
19. Drici MD, Wang WX, Liu X, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998;18:477-81.
20. Ross BD. Perfusion techniques in biochemistry. Oxford: Clarendon Press, 1992.
21. Logan FA, Herrington RN, Mackie MMS, Rubin PC. Pimozide: adverse reaction and prolonged half-life. Br J Psychiatry 1982;140: 433-4.
22. Inaba T, Nebert DW, Burchell B, Watkins PB, Goldstein JA, Bertilsson L, Tucker GT. Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995;73:331-8.
23. von Bahr C, Movin G, Nordon C, Laden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjoqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-40.
24. Llerena A, Dahl M-L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
25. Henthorn TK, Benitez J, Avram MJ, Martinez C, Llerena A, Cobaleda J, Krejcie TC, Gibbons RD. Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis. Clin Pharmacol Ther 1989;45:328-33.
26. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269: 15419-22.
27. De Morais SMF, Goldstein JA, Xie H-G, Huang S-L, Lu Y-Q, Xia H, Xiao Z-S, Ile N, Zhou H-H. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11.
28. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. JAMA 1993;269:1550-2.
29. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsades de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4.
30. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 1995;309:315-6.
31. Leestma JE, Koenig KL. Sudden death and phenothiazines: a current controversy. Arch Gen Psychiatry 1968;18:137-48.
32. Kemper AJ, Dunlap R, Pietro DA. Thioridazine-induced torsade de pointes. JAMA 1983;249:2931-4.
33. The Committee on Safety of Medicines. Pimozide dosage adjustments. Pharm Newsl 1995;21.
34. McIntyre IM, King CV, Staikos V, Gall J, Drummer OH. A fatality involving moclobemide, sertraline, and pimozide. J Forensic Sci 1997;42:951-3.
35. Desta Z, Flockhart DA. Commentary on McIntyre IM, King CV, Staikos V, Gall J Drummer OH. A fatality involving moclobemide, sertraline, and pimozide. J Forensic Sci 1999;44:231-2.
36. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 1996;16:101-3.
37. Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994;58:725-7.
38. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-56.
39. Wang RW, Newton DJ, Scheri TC, Lu AYH. Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation. Drug Metab Dispos 1997;25:502-7.
40. Ortiz de Montellano PR, Mico BA, Mathews JM, Kunze KL, Miwa GT, Lu AY. Selective inactivation of cytochrome P450 isoenzymes by suicide substrates. Arch Biochem Biophys 1981;210: 717-28.
41. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995;25:261-70.
42. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
43. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics pharmacodynamics of pimozide in healthy poor and extensive metabolizers cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
44. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin influence of female sex. JAMA 1998;280:1774-6.
45. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandell J, Nordlie J, Phillips RA. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-30.
46. Chen Y, Flockhart DA, Salcedo JA, Trapnell CB, Hall JE, Woosley RL. A metabolite of pentamidine blocks human cardiac potassium channels [abstract]. Clin Pharmacol Ther 1995;57:194.
47. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients recieving the systemic antimyotics ketoconazole and itraconazole. Clin Pharmacol Ther 1994;55:481-5.
48. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
49. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
50. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514-9.